DiaMedica Therapeutics Inc. (DMAC)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
7. 30
+0.17
+2.3843%
$
400.35M Market Cap
- P/E Ratio
- Div Yield
199,800 Volume
-0.72 Eps
$ 7.13
Previous Close 
Want to track DMAC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point
An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025. The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032. Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025.
Seekingalpha | 2 years ago
